荣昌生物制药（烟台）股份有限公司致力于发现、开发和商业化同类首创(first-in-class)和同类最佳 (best-in-class)的生物药物，不断创造新的临床价值，满足尚未被满足的重大临床需求，成为全球生物制药行业的领军企业。
Employees: 11-50
Investors 2
| Date | Name | Website |
| - | LAV | lavfund.co... |
| 09.02.2022 | Matrix Par... | matrixpart... |
Mentions in press and media 17
| Date | Title | Description |
| 27.09.2023 | Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis | YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently announced that Telitacicept(RC18)... |
| 25.07.2023 | RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal | YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has announced that their Phase II clinical ... |
| 10.07.2023 | RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors | The partnership focuses on combining novel antibody-drug conjugates RC88 and RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "... |
| 05.06.2023 | RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name | The "B" marker is removed from the Company's stock short name YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a fully-integrated commercial-sta... |
| 26.04.2023 | RemeGen Celebrates World Intellectual Property Day 2023 | YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, is celebrating World Intellectual Property Day 2023 which fal... |
| 28.02.2023 | On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy | YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare dis... |
| 13.12.2022 | RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA | YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced on December 7, 2022, that its latest antibody-drug c... |
| 17.11.2022 | RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines | YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced on November 5 that the Company's self-develo... |
| 01.11.2022 | RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients | YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its p... |
| 13.10.2022 | RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis | YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has... |
Show more